Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind trial of IBI301 + CHOP vs rituximab + CHOP in previously untreated DLBCL
CTR20160493Phase 3Completed
- Sponsor
- InnoCare Pharma
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IBI301 in diffuse large B-cell lymphoma (DLBCL), sponsored by InnoCare Pharma. Started Aug 2016; status: completed.
02
Drugs
IBI301
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20160493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160493.